Loading
A phase 2 trial of Sunvozertinib in non-small-cell lung cancer and small-cell lung cancer, run by Dizal Pharmaceuticals, active and no longer recruiting.
Sunvozertinib (DZD9008) in Pretreated Lung Cancer Patients with EGFR Exon20 Insertion Mutation (WU-KONG6) is a phase 2 interventional study registered as NCT05712902 by Dizal Pharmaceuticals, with 104 participants enrolled, started 2021-07-19 and due to reach its primary completion in 2022-10-17. Interventions recorded: Sunvozertinib. Conditions listed: Non-Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
Shares Sunvozertinib, Dizal Pharmaceutical, EGFR-mutated non-small-cell lung cancer, Small-cell lung cancer.
Shares Sunvozertinib, Dizal Pharmaceutical, EGFR-mutated non-small-cell lung cancer, Small-cell lung cancer.
Shares Sunvozertinib, Dizal Pharmaceutical, EGFR-mutated non-small-cell lung cancer, Small-cell lung cancer.
Shares Sunvozertinib, Dizal Pharmaceutical, EGFR-mutated non-small-cell lung cancer, Small-molecule kinase inhibitors.
Shares Sunvozertinib, Dizal Pharmaceutical, EGFR-mutated non-small-cell lung cancer, Small-cell lung cancer.
Shares Sunvozertinib, Dizal Pharmaceutical, Small-cell lung cancer, Small-molecule kinase inhibitors.
Shares Sunvozertinib, Dizal Pharmaceutical, EGFR-mutated non-small-cell lung cancer.
Shares Dizal Pharmaceutical, EGFR-mutated non-small-cell lung cancer, Small-cell lung cancer, Non-small-cell lung cancer.